Galderma has launched Sculptra (poly-L-lactic acid) in India, marking the company's entry into the regenerative aesthetics segment in one of Asia's fastest-growing aesthetic markets. Sculptra is a FDA-cleared biostimulator that stimulates collagen production over time, with results visible over 3–6 months and lasting up to 2 years.
Injectables
Galderma Launches Sculptra in India—Regenerative Expansion
Poly-L-lactic acid biostimulator enters India market as Galderma builds APAC footprint.
India's aesthetic market expands 15%+ annually; biostimulators command higher margins.
The India launch reflects Galderma's strategy to diversify beyond its core dermal filler and toxin portfolio into longer-acting, higher-margin biostimulators. India's aesthetic market is expanding at 15%+ annually, driven by rising disposable income and social-media-driven demand. Sculptra's mechanism—collagen induction rather than volume replacement—appeals to practitioners seeking differentiation and to patients willing to invest in multi-session protocols. Galderma's distribution network and regulatory relationships position it to capture share ahead of smaller competitors in a market where brand trust and supply reliability are critical.
Source: original report ↗
Frequently asked questions
How long does Sculptra last and when do results show up?
Results from Sculptra become visible over 3–6 months as the poly-L-lactic acid stimulates collagen production, with effects lasting up to 2 years. This gradual timeline differs from traditional fillers, making it ideal for patients seeking natural-looking, sustained rejuvenation.
What is the difference between Sculptra and dermal fillers?
Sculptra is a biostimulator that works by inducing collagen production rather than adding volume directly like traditional fillers. This regenerative mechanism creates longer-lasting results (up to 2 years) and appeals to practitioners wanting to differentiate their offerings with a more natural aging reversal approach.
Is Sculptra FDA-cleared and approved in India?
Yes, Sculptra is FDA-cleared in the United States. Galderma has now launched it in India as part of its expansion into the regenerative aesthetics segment, leveraging its established regulatory relationships and distribution network in the region.
How fast is India's aesthetic market growing?
India's aesthetic market is expanding at 15%+ annually, driven by rising disposable income and social-media-driven demand for cosmetic procedures. This rapid growth makes it one of Asia's fastest-growing aesthetic markets and a strategic priority for major players like Galderma.
Why are biostimulators like Sculptra higher-margin products?
Biostimulators command higher margins because they require multi-session treatment protocols and deliver longer-lasting results (up to 2 years), creating recurring revenue opportunities and stronger patient lifetime value compared to single-session traditional fillers.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.